New pill may boost vision in wet AMD patients
NCT ID NCT07695207
First seen Jul 10, 2026 · Last updated Jul 10, 2026
Summary
This Phase 3 trial tests whether adding an SMZ1 tablet to standard ranibizumab eye injections improves vision more than injections alone in people with wet age-related macular degeneration (AMD). Participants receive either SMZ1 or a placebo tablet twice daily for 12 months, along with monthly ranibizumab injections for the first 3 months and then as needed. The main goal is to measure changes in best-corrected visual acuity after one year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SMZ1 tablet
- What this could lead to
- If successful, this combination therapy could offer better vision improvement for people with wet age-related macular degeneration than standard injections alone.
- What could go wrong
- This is a Phase 3 trial, but results may not confirm benefit. Risks include side effects from the drug or injections, and the treatment may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION WITHOUT POLYPOIDAL CHOROIDAL VASCULOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Kyung Hee University Hospital
RECRUITINGSeoul, Seoul, 02447, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••